Alternatives to chemotherapy and radiotherapy as adjuvant treatment for lung cancer

Lung Cancer

Volumn 17, Issue SUPPL. 1, 1997, Pages

  Shepherd, Frances A ^a,b,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Adjuvant therapy; Angiogenesis; Immunotherapy; Lung cancer; Retinoids

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BCG VACCINE; BETA CAROTENE; CORYNEBACTERIUM PARVUM EXTRACT; IMMUNOSTIMULATING AGENT; INTERFERON; LEVAMISOLE; RETINOID; TUMOR VACCINE; VITAMIN;

ADJUVANT THERAPY; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; IMMUNOTHERAPY; LUNG CANCER; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; BCG VACCINE; CHEMOPREVENTION; CHEMOTHERAPY, ADJUVANT; CYTOKINES; GENE THERAPY; HUMANS; IMMUNOTHERAPY; LEVAMISOLE; LUNG NEOPLASMS; VITAMINS;

EID: 0030978426     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00646-6     Document Type: Conference Paper

References (45)

1. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised trials. Br Med J 1995; 311: 899-909.
2. Takita H. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma. J Thorac Cardiovasc Surg 1970; 59: 642-644.
3. Ruckdeschel J, Codish S, Stranahan A, McKneally M. Post-operative empyema improves survival in lung cancer. N Engl J Med 1972; 287: 1013-1017.
4. Pass H, Pass H. Lung cancer biotherapy: specific and non-specific mechanisms. In: Pass HI, Mitchell JB, Johnson DH and Turrisi AT, editors. Lung Cancer: Principles and Practice. Philadelphia: Lippencott-Raven, 1996: 917-930.
5. Mountain CF, Gail MH. Surgical adjuvant intrapleural BCG treatment for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg 1981; 82: 649-657.
6. Ludwig Lung Cancer Study Group. Immunostimulation with intrapleural BCG in resected non-small cell lung cancer. Cancer 1986; 58: 2411-2416.
7. Miller AB, Taylor HE, Baker MA. Oral administration of BCG as an adjuvant to surgical treatment of carcinoma of the bronchus. Can Med Assoc J 1979; 121: 45-54.
8. Ludwig Lung Cancer Study Group. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 1985; 89: 842-847.
9. Study Group for Bronchogenic Carcinoma. Immunopotentiation with levamisole in resectable bronchogenic carcinoma: a double blind controlled trial. Br Med J 1975; 3: 461-464.
10. Wright PW, Hill LD, Peterson AV Jr. Preliminary results of combined surgery and adjuvant bacillus Calmette-Guerin plus levamisole treatment of resectable lung cancer. Cancer Treat Rep 1978; 62: 1671-1675.
11. Amery WK. Final results of a multicenter placebo-controlled levamisole study of resectable lung cancer. Cancer Treat Rep 1978; 62: 1677-1683.
12. Anthony HM, Mearns AJ, Mason MK. Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure. Thorax 1979; 34: 4-12.
13. Holmes EC, Hill LD, Gail M. Randomized comparison of the effects of therapy on resected stage II and III non-small cell carcinoma of the lung. Ann Surg 1985; 202: 335-341.
14. Mattson K, Niirinen A, Pyrhonee S. Natural interferon alfa as maintenance therapy for small cell lung cancer. Eur J Cancer 1992; 8/9: 1387-1391.
15. Jett JR, Su JQ, Maksymiuk AW. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer. J Clin Oncol 1994; 12: 2321-2326.
16. Kelly K, Crowley J, Bunn P. Role of recombinant interferon alfa-2a maintenance in patients with limited stage small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1995; 13: 2924-2930.
17. Parkinson DR. Present status of biological response modifiers in cancer. Am J Med 99 1995; (Suppl 6A): 53S-54S.
18. Tursz T. Combination of BRMs with chemotherapy. Am J Med 1995; (Suppl 6A): 56S-58S.
19. Kimura H, Yamaguchi Y. Randomized controlled study with interleukin 2 and lymphokine activated killer cells against postoperative primary lung cancer patients [abstract]. Lung Cancer 1994; 11: 187.
20. 389 11-2 mechanism and kinetics of action: in vitro and in vivo preclinical studies. Proc Lilly Oncol Global Med Conf 1995; 45.
21. Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 1994; 12: 851-873.
22. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
23. Omenn GS, Goodman G, Thornquist M. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
24. Hennekens C, Buring J, Manson J. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Eng J Med 1996; 334: 1145-1149.
25. Hong WK, Lippman SM, Itri LM. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
26. Pastorino U, Infante M, Maioli M. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993; 1216-1222.
27. Folkman J. Clinical applications of research on angiogenesis. N Eng J Med 1995; 333: 1757-1763.
28. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-cancer agents. Adv Enzyme Regul 1995; 35: 293-301.
29. Stahel RA, Gilks WR, Schenker T. Antigens of lung cancer: results of the third international workshop on lung tumor and differentiation antigens. J Natl Cancer Inst 1994; 86: 669-672.
30. Stein R, Goldenberg DM. Prospects for the management of non-small-cell carcinoma of the lung with monoclonal antibodies. Chest 1991; 99: 1466-1476.
31. Y cell surface antigens. Cancer Res 1990; 50: 2183-2190.
32. Schreiber GJ, Hellstrom K, Hellstrom I. An unmodified anticarcinoma antibody, BR96, localized to and inhibits the outgrowth of human tumors in nude mice. Cancer Res 1992; 52: 3262-3266.
33. Friedman P, Chace D, Trail P, Siegall C. Antitumor activity of the single chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts. J lmmunol 1993; 150: 3054-3061.
34. Epstein C, Lynch T, Shefner J. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer 1994; 8 (Suppl): 57-97.
35. Lynch TJ. Immunotoxin therapy of small cell lung cancer. Chest 1993; 103 (Suppl): 436S-439S.
36. Trail P, Willner D, Lasch SJ. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993; 261: 212-215.
37. Mulshine J, Avis I, Treston AM. Clinical use of a monoclonal antibody to bombesin-like peptide in patients with lung cancer. Ann NY Acad Sci 1988; 547: 360-372.
38. Moulder JE, Rockwell SS. Tumor hypoxia: its impact on cancer therapy. Cancer Metast Rev 1987; 5: 313-341.
39. Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW. S-4233: a new bioreductive agent with highly selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 1986; 12: 1239-1242.
40. Rodrigues GI, Lockwood H, Von Hoff DD. A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 382.
41. Dalton WS. Is p-glycoprotein a potential target for reversing clinical drug resistance? Cur Opin Oncol 1994; 6: 595-600.
42. Ford JM. Pharmacologic circumvention of multidrug resistance. Cytotechnology 1993; 12: 171-212.
43. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996; 23: 101-107.
44. Arca MJ, Mule JJ, Chang AE. Genetic approaches to adoptive cellular therapy of malignancy. Semin Oncol 1996; 23: 108-117.
45. Abrams SI, Hand PH, Tsang KT, Schlom J. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996; 23: 118-134.